mrna-0184
Nucleic acidexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 18, 2022 (NCT05659264)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Relaxin receptor 1Supplementation
RXFP1 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068586 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06655870 | Phase 1 | Oct 29, 2024 | Moderna Therapeutics |
| NCT06243770 | Phase 1 | Feb 16, 2024 | Moderna Therapeutics, Nucleus Network Ltd |
| NCT05659264 | Phase 1 | Nov 18, 2022 | Moderna Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Moderna Therapeutics | For profit | 3 | 3 | 1 | 2022 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1